Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Regeneron loses key defense in COVID-19 treatment patent lawsuit Legalcategory· October 4, 2024 The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

However, Pfizer decided not to pursue approval due to questions about its potential commercial performance. To address these challenges, the EMA launched a pilot programme in 2022 to support academic ...

Sanofi has claimed approval in the EU for Xenpozyme as a treatment for acid sphingomyelinase deficiency (ASMD) – which becomes the first and only treatment option for patients with the rare disease.

To date, dupilumab has been studied across more than 60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by type-2 inflammation. In addition to the ...

His leadership was instrumental in securing the fastest FDA and EMA approval for Tagrisso in non-small cell lung ... Genmab, and Aventis (Sanofi). During his academic career he was a Professor in ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Gardasil has also been licensed in over 40 countries worldwide. Cervarix is awaiting European Medicines Agency (EMEA) approval, as well as that of the FDA. If their submission is 'fast-tracked ...

announced it has received approval for its Phase 2 clinical trial from the European Medicines Agency (EMA). NTRX-07, the Company's lead molecule, will be administered to Alzheimer's disease (AD) ...